TuHURA Biosciences (HURA) announced that it has entered into a definitive agreement for the purchase of an aggregate of 9,462,423 shares of its common stock, Series A warrants to purchase up to an aggregate of 9,462,423 shares of its common stock and Series B warrants to purchase up to an aggregate of 9,462,423 shares of its common stock, at a purchase price of $1.65 per share and accompanying warrants in a registered direct offering. The warrants will have an exercise price of $1.95 per share and will be exercisable beginning six months after the date of issuance. H.C. Wainwright & Co. is acting as the exclusive lead placement agent for the offering. Rodman & Renshaw is acting as co-placement agent for the offering.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HURA:
- TuHURA Biosciences presents research on potential role of DOR at ASH
- TuHURA Biosciences Amends Loan Agreement, Secures Full $3M
- TuHURA Biosciences’ Shelf Registration Statement Effective
- TuHURA Biosciences Completes Acquisition of Kineta, Inc.
- TuHURA Biosciences Reports Q3 Financials and Advances Cancer Therapy Trials